NTRC Therapeutics rebrands itself to Crossfire Oncology

NTRC Therapeutics, a biotech company specialized in the research and development of kinase inhibitors and degraders, will continue under the name Crossfire Oncology.

Founded in 2011 as Netherlands Translational Research Center, NTRC originally pursued a dual business model providing services to

11 September 2023|